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ABSTRACT 
Phosphatidylinositide (PI) 3-kinase, a heterodimer composed of a p110 catalytic 
subunit and a p85 regulatory subunit, possesses activities that have been subsequently 
found in eukaryotic cell types and are involved to an incredible diverse characteristic of 
key cellular functions, including cell growth, proliferation, motility, differentiation and 
survival. An emerging association between PI3K and human diseases, especially cancer, 
brings more and more attention of focus on intense study. An increasing number of 
human cancer cell lines has been proved to harbor PI3K mutant, resulting in easily 
occurring shift of anti-drug cellular characteristic caused by simulative activation and 
overexpression of PI3K. Thus, inhibition of PI3K is considered potential therapeutic 
options. Food phytochemicals, such as organosulfur compound, have considered as 
promising candidates for health promoting food chemicals in recent years. Among them, 
benzyl isothiocyanate (BITC), one of the isothiocyanate (ITC), has been shown to have 
antiproliferative properties against a variety of cell lines. Based on this concept, to 
investigate BITC as an anti-cancer agent against PI3K-related cellular responses, I 
demonstrate that regulation of PI3K is an effective strategy for controlling PI3K-
associated cellular pathway and activities. 
In Chapter 2, I clarified the role of phosphoinositide 3-kinase (PI3K) in 
antiproliferation induced by benzyl isothiocyanate (BITC) in human colorectal cancer 
cells (HCT-116, HT-29, DLD-1).  BITC simultaneously activated the 
PI3K/Akt/forkhead box O (FoxO) pathway, whereas it significantly inhibited the 
proliferation in HCT-116 cells.  Inhibitory experiments using a PI3K selective inhibitor, 
LY294002 or NVP-BEZ235, significantly enhanced the BITC-induced antiproliferation 
and apoptotic cell population with the attenuation of the BITC-induced activation of the 
PI3K/Akt/FoxO survival pathway.  Furthermore, BITC enhanced the insulin-activated 
PI3K/Akt/FoxO pathway, possibly through its inhibition of the protein tyrosine 
phosphatase 1B enzymatic activity.  Taken together, these results suggested that the 
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PI3K/Akt/FoxO pathway negatively regulates the BITC-induced antiproliferation in 
human colorectal cancer cells. 
In chapter 3, I investigated the regulating role of autophagy in benzyl 
isothiocyanate (BITC)-induced Nrf2 activation, laying a pivotal role in the inducible 
expression of cytoprotective genes.  BITC not only Time-dependently (12h) but also 
dose-dependently induced autophagy, concomitantly with Keap1/Nrf2 modulation in 
human colorectal cancer HCT-116 cells. Immunofluorescence results suggested that 
BITC induced the formation of autophogosome and lysosome, which is also confirmed 
by positive BITC-induced formation of autophagic vacuoles by using MDC staining.   
Experiments using a phosphatidylinositide 3-kinase (PI3K)-specific inhibitor suggested 
inhibition of PI3K not only attenuated BITC-induced accumulation of autophagic 
molecules, but also compromised autophagy-related p62-Nrf2-Keap1axis induced by 
BITC. On the other hand, inhibitory experiments revealed that HO-1 gene, a 
cytoprotective gene, was also involved in PI3K-related autophagic induction. Taken 
together, these results suggested that PI3K plays the key role in the autophagy-
dependent Nrf2 activation by BITC. 
   My findings provide biological evidences that (1) regulation of PI3K plays an 
essential role not only in the BITC-induced PI3K/Akt survival pathway but also in the 
enhancement of anti-proliferative effects by BITC against BITC-induced drug-resistance 
in HCT-116, HT-29 and DLD-1 human colon cancer cells; (2) PI3K is involved in 
induction of autophagy by BITC and also regulates autophagy-related p62/Nrf2/Keap1 
axis and expression of cytoprotection genes in HCT-116 human colon cancer cells. Taken 
together, these studies proposed that regulation of PI3K is a promising strategy to 
overcome resistance of food-derived compounds activating PI3K/Akt and Nrf2 pathway 
in human colon cancer cells. 
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CHAPTER 1 
General Introduction 
1.1 Benzyl isothiocyanate 
A number of researches support that certain food phytochemicals protect against 
cancer. An important group of chemicals that possess this property are organosulfur 
compound, such as isothiocyanates (Fahey et al., 2001). Isothiocyanates, naturally 
occurring in abundance in cruciferous vegetables such broccoli, watercress, Brussels 
sprouts, cabbage, Japanese radish, and cauliflower, may plays a significant role in 
affording the cancer chemopreventive properties of these vegetables (Nakamura et al., 
2007b). Based on these anti-cancer properties that ITCs have, through different 
mechanism including induction of phase 2 detoxifying enzyme, induction of apoptosis, 
inhibition of cell cycle progress and induction of anti-inflammatory activity (Miyoshi et 
al., 2004a; Nakamura et al., 2002), ITCs exhibit a promising cancer chemotherapeutic 
effects on a variety of cancer cell types. Benzyl isothiocyanate (BITC), an isothiocyanate 
compound which is a hydrolysis product of the glucosinolate glucotropaeolin (Bennett et 
al., 1997) derived from cruciferous vegetables, has been shown to have anti-carcinogenic 
properties. BITC is also potent in suppressing proliferation by causing DNA damage, 
G2/M cell arrest and apoptosis in many cancer cell lines, including pancreatic cancer 
(Sahu et al., 2009) and prostate cancer (Lin et al., 2013).    
1.2 Colorectal cancer 
Colorectal cancer (CRC), also known as bowel cancer or colon cancer, has been 
announced to be the second most common cancer worldwide by the World Health 
Organization and CDC. Due to its mortality rate, CRC persists as one of the most deadly 
and prevalent tumor types in both women and men around the world (Hammond et al., 
2016). Including CRC, metastatic disease is considered incurable. In spite of advances in 
systemic therapy, the 5-year survival rate is still a mere 12.5% (Siegel et al., 2014), even 
though patients are typically given a combination of cytotoxic chemotherapy with a target 
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therapy. The primary reason for cancer failure are commonly considered to be an acquired 
resistance that contributes to nearly 90% of the patients with such occurring anti-drug 
resistance during the chemotherapeutic treatment (Longley and Johnston, 2005).   
1.3 Drug resistance 
Malignant tumor can have intrinsic resistance and/or acquired resistance and each of 
them is essential in determining initial and subsequent lines of treatment. Between these 
two types of resistance, tumors might intrinsically initialize drug-resistance or develop 
acquired resistance to chemotherapy during treatments (Longley and Johnston, 2005). 
Acquired resistance is a particular problems to patients, as tumors not only turn into 
resistant to original treatment, but also can obtain cross-resistant to  
Fig. 1.1 Schematic model of drug-induced cell resistance 
 
the other chemotherapy with different mechanism of actions. These factors are believed 
to contribute to a fact that the drug-treatment failure remains still stubbornly high with 
even multiple kinds of mechanism of chemotherapy during the treatments.  
    In the chemotherapeutic process, each cytotoxic therapy and each targeted pathway 
may result in different mechanism of acquired resistance, but acquired resistance to one 
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drug often confers resistance to the other drug that even acts in a different targeting 
mechanism, which refers to a concept as multidrug resistance (MDR) (Hammond et al., 
2016). Different mechanism is involved in resistance to targeted therapies, including 
upregulation, mutation or activation of downstream signaling molecules within specific 
pathways (Tejpar et al., 2012). The shortage of understanding the mechanisms of acquired 
drug resistance to targeted therapies still remains to issues that obstructively develop 
future therapies.      
1.4 PI3K/Akt survival pathway 
Phosphatidylinositide 3-kinase (PI3K)/Akt is a potential survival pathway that may 
regulate resistance to the apoptotic effects of chemotherapy drugs and radiation therapy 
in a variety of cancer cell lines (Boreddy et al., 2011). Despite how much advancement 
in chemo- and radio- therapy, PI3K/Akt pathway still remains highly reality of anti-drug 
properties to clinical treatment. Such existence of PI3K/Akt-related resistance could be 
contributed by hyperactivation of Akt in particular cell lines, or ether be activated 
exogenously by growth factor, cytokines or anti-cancer reagent (Hossini et al., 2016). 
Both apoptosis and survivals of cells could be controlled by proteins including Akt 
involved in PI3K pathway. After full activation of Akt, phosphorylated Akt enhances 
survival and inhibits apoptosis through phosphorylation and deactivation of several anti- 
and pro- apoptotic target proteins, including mTOR, FoxO families, pro-apoptotic BAD, 
a regulative ratio of Bcl-2 and BAX genes and tumor suppressor p53. 
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Fig. 1.2 Schematic model of PI3K/Akt/FoxO survival pathway  
1.4.1 Receptor tyrosine kinase 
     Receptor tyrosine kinases (RTKs), a family of cell surface receptors, have emerged 
as key regulators of critical cellular processes, such as proliferation and differentiation, 
cell survival and metabolism, cell migration, and cell cycle control (Blume-Jensen and 
Hunter, 2001). All RTKs have a similar molecular architecture, with a ligand-binding 
region in the extracellular domain, a single transmembrane helix, and a cytoplasmic 
region that contains the protein tyrosine kinase (TK) domain plus additional carboxy (C-) 
terminal and juxtamembrane regulatory regions (Lemmon and Schlessinger, 2010). 
Numerous human diseases, including cancers, diabetes, inflammation, have been causally 
linked to mutation of RTKs and aberrant activation of its intracellular signaling pathway 
that alter cellular activities. Among these RTKs, the insulin receptor and IGF-1 are 
expressed on the cell surface as disulfide-linked (αβ)2 dimers (Ward et al., 2007). Binding 
of insulin and IGF-1 results in structural changes and stimulates tyrosine kinase activity, 
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which leads to activation of the intracellular tyrosine kinase domains and cell signaling 
pathway, including PI3K/Akt survival pathway.  
1.4.2 Role of Akt in PI3K/Akt pathway 
   Akt/protein kinase B (PKB) is a serine/threonine protein kinase that functions as a 
critical regulator of cell survival and proliferation, which has emerged as central role in 
the signaling transduction (Brazil and Hemmings, 2001). Two phosphorylation sites, 
Th308 in the activation loop within the kinase domain and Ser473 in the C-terminal 
regulatory domains, are contained in all the Akt/PKB isoforms except for Akt3. 
Activation of PI3-kinase by stimuli, such as growth factor and anti-cancer reagent, 
contributes to activation of Akt at the Thr308 site through signaling transduction of PDK1. 
Phosphorylation of Thr308 partially activates Akt, while full activation needs 
phosphorylation of both sites.      
1.4.3 Transcriptional factor FoxO 
   The Forkhead (FoxO) family of transcriptional was first identified from genetic 
analysis of C.elegans (Paradis and Ruvkun, 1998), which has now been identified in 
several different organism, including Caenorhabditis elegans, zebrafish, Drosophila, 
mouse, rat and humans (Van Der Heide et al., 2004). FoxO factors can regulated by 
several signal transduction cascades. Among these cascades, PI3K pathway plays a 
primary role in controlling the phosphorylation of FoxO factors and its intracellular 
localization and transcriptional functions. Once PI3K/Akt pathway is activated, the 
activated Akt detaches from the cellular membrane and translocates to the cytosol and 
nucleus, where it phosphorylates serine or threonine residues within its motif and gets 
ready to transduce signals to its downstream target proteins (Lawlor and Alessi, 2001). 
Within the structure of FoxO families, including murine FoxO1, FoxO3, FoxO4, and 
FoxO6, three highly conserved putative Akt recognition motifs are contained for those 
phosphorylation by Akt. All the FoxO proteins require the consensus N-terminal Akt site 
and Akt site located in the forkhead domain to translocate form nucleus to cytosol 
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(Brownawell et al., 2001). The phosphorylated FoxO factors can regulate cell survival 
thought controlling its target genes that may be important in the inhibitory effect of cell 
survival.       
1.4.4 PTP1B and its involvement in PI3K/Akt pathway 
  Protein tyrosine phosphatase 1B (PTP1B) is a ubiquitously expressed phosphatase that 
has emerged as a relevant regulator of signaling cascade initiated by the activation of the 
tyrosine kinase receptor families (Haj et al., 2003). It has an N-terminal catalytic domains, 
two proline-rich sequences, and a C-terminal hydrophobic region (He et al., 2014). Due 
to its capability to dephosphorylate and inactivate the insulin receptor (IR), PTP1B is a 
critical role of insulin signaling through switching off insulin signaling (Salmeen et al., 
2000). Recent studies have shown that small molecule inhibitors of PTP1B increase 
insulin-stimulated IR and IRS (insulin receptor substrate) phosphorylation (Ahmad et al., 
1995; Zhang and Zhang, 2007), suggesting that inhibition of PTP1B might sensitize 
insulin-related pathway. In addition, given its function in dephosphorylation of RTKs that 
are responsible for inducing oncogenic signaling and drug-induced resistance, PTP1B has 
always been considered as a potential tumor suppressor. However, studies also revealed 
that PTP1B can promote tumorigenesis (Lessard et al., 2010). Therefore, understanding 
the connection between PTP1B activities and anti-cancer reagent seems to be an 
important potential strategy for the cancer therapy.      
1.5 MEK/ERK cascade 
The Ras/Raf/MEK/ERK cascade transduces signals from cell surface receptors to 
transcriptional factors, which regulate gene expression. Furthermore, this cascade also is 
responsible for regulating the activity of many proteins involved in drug-resistance and 
apoptosis. Due to such functions of MEK/ERK pathway, it is also considered to have 
profound effects on the regulation of apoptosis by the post-phosphorylation of apoptotic 
regulatory molecules, including Bad, Bim, caspase-9 and Bcl-2 (Mccubrey et al., 2007). 
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Therefore, this pathway has diverse effects that can regulate apoptosis, cell growth, cell 
cycle progression and differentiation. For the reasons described above, MEK/ERK has 
been believed to be an important pathway to target for the cancer therapy in the clinical 
trials. However, many studies show a dual effect on cell proliferation (Marshall, 1999). 
It is shown to promote cell proliferation by inducing the expression of cyclin D and 
enhance the activation of cell cycle kinases (Cheng et al., 1998; Lavoie et al., 1996). In 
addition, ERK can interfere with apoptosis on several levels, including preventing 
activation of caspases (Tran et al., 2001) and inducing the expression of anti-apoptotic 
factors. Furthermore, many anti-drugs show that they can activate MEK/ERK cascade, 
which has negative role in regulating cell cycle progression and drug-induced apoptotic 
effects (Boldt et al., 2002). Due to the discoveries above, the modulative functions of 
MEK/ERK to efficacy of chemotherapeutic drugs seem to be considered cell line-
dependent and anti-cancer drug-dependent.  
1.6 Autophagy 
   Autophagy is a self-degradative progress that is essential for cellular homeostasis at 
critical time in development and in response to nutrient condition, oxidative stress and 
cytotoxicity(Glick et al., 2010) through clearing damaged organelles, degrading 
misfolded proteins, as well as eliminating intracellular pathogens. There are three 
commonly defined types of autophagy: micro-autophagy, macro-autophagy and 
chaperone- mediated autophagy, which are considered to be responsible for different type 
of cellular stress, respectively. Macroautophagy delivers cytoplasmic cargo to the 
lysosome against streess acquired by anti-cancer chemicals through intermediation by a 
double-membrane vesicle, refered to as an autophagosome, which can fuse with lysosome 
to form an autophogolysosome that finally be able to degreade and eliminate unnecessary 
intracellular components. For the procedure described above, several primary steps are 
necessary, such as formation of autophagosome and lysosome, as well as fusion of 
autophagosome and lysosome (Glick et al., 2010).      
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1.6.1 Autophagosome and lysosome 
    Autophagosome is a double-membrane spherical structure that is the key structure 
in macroautophagy. The initial step for formation of autophagosome needs endoplasmic 
reticulum, followed by elongation of structures called phagophores (Kruppa et al., 2016). 
The formation of autophagosome is controlled by Atg genes through conjugation of 
Atg12-Atg5 and LC3 (Microtubule-associated protein 1A/1B-light chain 3). LC3 proteins 
are originally identified as one of three light chains (LC1, LC2 and LC3). During the 
progress of formation of autophagosomal membrane, cytosolic LC3 (LC3-I) is 
conjugated to phosphatidylethanolamine (PE) (Sou et al., 2006) by two consecutive 
ubiquitylation-like reaction catalyzed by the E1-like enzyme Atg7 and E2-like enzyme 
Atg3 (Tanida et al., 2004, 2001) to LC3- II.  
   Lysosomes are intracellular membrane-bound organelles that receive misfolded 
proteins, damaged organelles and pathogens delivered by endocytosis, phagocytosis and 
autophagy for degradation and recycling to maintain intracellular homeostasis (Piao and 
Amaravadi, 2016). Although recent studies investigated by many research groups show 
that luminal lysosomal hydrolases, lysosomal membrane proteins have been found to 
have indispensable functions. Among these proteins, more than 25 proteins have been 
identified (Saftig and Klumperman, 2009), with the most abundant lysosomal membrane 
proteins, lysosome-associated membrane protein 1 (LAMP-1) and LAMP-2, which 
represent 50% of all the membrane proteins within the lysosome (Saftig et al., 2010). 
These proteins are essential for lysosomal biosynthesis, lysosomal acidification and 
fusion with autophagosome. Once maturation of autophagosome and lysosome occurs, 
lysosome serve as the terminal station with the most acidic pH of 4.5 for the lysosome-
related autophagic pathway.    
1.6.2 Involvement of PI3K in autophagy 
   In mammalian cells, there are different classes of PI3K (phosphatidylinositide 3-
kinase) that regulate autophagy. VPS34, a catalytic subunit of phosphatidylinositide 3-
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kinase complexes (Itakura et al., 2008), phosphorylates phosphatidylinotisol to form 
phosphatidylinotisol-3-phosphate (PtdIns3P), which enables the synthesis of 
autophagosomes. Vps34 has been found to play an essential role in endocytosis, 
autophagy and mTOR activation (Burman and Ktistakis, 2010), which has been 
established largely by the use of the pharmacological inhibitors wortmannin and 3-
methyladenine (3-MA) that are utilized as a suppressor to autophagy in many studies. 
However, due to these specificities of these inhibitors, the precise mechanism between 
Vps34 and anti-cancer reagent stills remains unclear.  
1.6.3 p62-dependent Nrf2/Keap1 noncononical pathway 
   The nuclear factor erytheroid-derived-2-like 2 (Nrf2)-Kelch-like like ECH-associated 
protein 1 (Keap1) pathway is a redox and xenobiotics sensitive signaling axis that protects 
cells against cellular toxicity, oxidative stress and harmful chemicals through the 
induction of cytoprotective detoxifying genes (Jiang et al., 2015). The crosslink between 
the Nrf2-Keap1-antioxidant-responsive elements (ARE) axis and autophagy was reported 
to have association with p62/sequestosome 1 (SQSTM1) and Keap1 several times 
(Komatsu et al., 2010a; Lau et al., 2010). However, in 2010, it is particularly discovered 
that p62 activates Nrf2 by a no-canical pathway (Lau et al., 2010). p62 regulates cellular 
redox hemostasis by binding to Keap1 and sequester Keap1 into the autophagosomes for 
degradation in an autophagy-dependent manner (Komatsu et al., 2010b), which attenuates 
the ubiquitylation of Nrf2, leading to its free accumulation and translocation into nuclear 
(noncanonical pathway) (Jiang et al., 2015). Hence, Nrf2 binds to ARE in the promoter 
regions of detoxifying and anti-oxidant genes (Ma, 2013), such as NQO-1 and HO-1.  
1.7 study outline 
    In the present study, I examined the effect of BITC on the 
phosphatidylinositide 3-kinase (PI3K)/Akt/forkhead box O (FoxO) survival pathway in 
human colorectal cancer cells (HCT-116, HT-29, DLD-1). I also investigated the 
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regulating role of autophagy in benzyl isothiocyanate (BITC)-induced Nrf2 activation, 
playing a pivotal role in the inducible expression of cytoprotective genes in human 
colorectal cancer HCT-116 cells and clarified the mediating role of PI3K in the 
autophagy-dependent Nrf2 activation by BITC. 
   My findings provide biological evidences that (1) BITC activates the 
PI3K/Akt/FoxO survival pathway, even though it significantly inhibits the proliferation 
in HCT-116 cells; (2) Inhibitory experiments using a PI3K selective inhibitor, 
LY294002 or NVP-BEZ235, significantly enhances the BITC-induced antiproliferation 
and apoptotic cell population with the attenuation of the activation of the PI3K/Akt/FoxO 
pathway; (3) BITC time- and dose-dependently induces autophagy, concomitantly with 
Nrf2 up-regulation in human colorectal cancer HCT-116 cells; (4) PI3K plays the key 
role in the autophagy-dependent Nrf2 activation by BITC in HCT-116 human colon 
cancer cells. Taken together, these studies propose that combinatory treatment with the 
PI3K inhibitors is a promising strategy to overcome resistance of food phytochemicals as 
well as anti-cancer agents, activating PI3K in human colon cancer cells. 
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CHAPTER 2 
Inhibition of phosphatidylinositide 3-kinase ameliorates antiproliferation by 
benzyl isothiocyanate in human colon cancer cells 
 
2.1 Introduction 
Phosphatidylinositide 3-kinase (PI3K), a heterodimer composed of a p110 catalytic 
subunit and a p85 regulatory subunit, catalyzes the phosphorylation of a plasma 
membrane lipid phosphatidylinositide-4,5-bisphosphate into phosphatidylinositide-
3,4,5-trisphosphates.  The phosphatidylinositide-4,5-bisphosphate phosphorylation by 
PI3K leads to the translocation and phosphorylation of Akt (Plastaras et al., 2008), a 
critical downstream target of PI3K which activates a variety of downstream targets 
including forkhead box O (FoxO) 1, mammalian target of rapamycin (mTOR), and 
ribosomal protein S6 (Schmidt et al., 2002).  Full activation of Akt is achieved after 
phosphorylation at the active site residues of Thr308 and Ser473 by phosphoinositide-
dependent kinase-1 and mTORC2, respectively (Comb et al., 2012).  Akt plays an 
important role in controlling cell survival, cell growth and cell proliferation (Zhang et 
al., 2016), possibly through modulating the function of numerous substrates, including 
mTORC1 (Troca-Marín et al., 2014), nuclear factor κB, and FoxO (Coomans de 
Brachène et al., 2014).  Among them, FoxO modulates the cell cycle arrest (induction 
of p21Cip1 and p27Kip1), apoptosis and DNA damage repair.   
Drug resistance, generally categorized as intrinsic or acquired, often limits the 
efficacy as well as outcome of chemotherapy.  In addition to the increasing efflux of 
the drug through ATP-dependent transporters (Gottesman et al., 2002), PI3K is another 
plausible molecule that mediates resistance to the chemotherapy drugs.  The PI3K-
mediated pathway is frequently activated (Boreddy et al., 2011; Fahy et al., 2003) and 
influences cell growth, survival and drug resistance (Jian et al., 2015) in a variety of 
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human cancer cells including colorectal cancer cells.  Excessive PI3K activation is 
mainly caused by genetic aberrations, such as the receptor-type tyrosine kinase 
overexpression, PIK3CA (PI3K catalytic subunit, alpha isoform) mutations and PTEN 
(Phosphatase and Tensin homolog deleted from chromosome 10) mutations and 
deletions, which are found in about 40% of large bowel tumors (Danielsen et al., 2015).  
Inhibition of PI3K with a classical inhibitor, wortmannin, reduced cell growth in a soft 
agar assay (Khaleghpour et al., 2004) and PI3K p85 knockdown increased the 
sensitivity to 5-fluorouracil in colon cancer cells (Sun et al., 2009).  Thus, the 
PI3K/Akt/FoxO pathway is one of the most attractive therapeutic targets to improve the 
therapeutic efficacy of anti-cancer drugs. 
Organosulfur compounds including isothiocyanates (ITCs) are an important and 
promising group of compounds that have a cancer-preventive property (Nakamura, 2009).  
Benzyl isothiocyanate (BITC), an ITC compound mainly derived from cruciferous 
vegetables, has been shown to have antiproliferative properties against a variety of cell 
lines including hepatocytes (Sugie et al., 1993), T lymphocytes (Miyoshi et al., 2004b), 
colon fibroblasts (Miyoshi et al., 2007), cervical epithelial cells(Miyoshi et al., 2008), 
renal proximal tubular cells (Abe et al., 2012), and colorectal cancer cells (Abe et al., 
2014; Sakai et al., 2012).  We previously found that BITC inhibits cell proliferation 
by inducing cell cycle arrest and apoptosis mainly via the mitogen-activated protein 
kinase (MAPK) pathways in several human cancer cell lines (Miyoshi et al., 2004b).  
However, the regulating role of the PI3K/Akt/FoxO pathway in antiproliferation by 
BITC in human colorectal cancer cells remains unclear. 
In the present study, we clarified the role of the PI3K/Akt/FoxO pathway in 
antiproliferation induced by BITC in human colorectal cancer cells.  We demonstrated 
that BITC inhibited the proliferation in human colorectal cancer HCT-116 cells, 
whereas it activated the PI3K/Akt/FoxO pathway.  Inhibitory experiments using a 
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PI3K selective inhibitor, LY294002 or NVP-BEZ235, indicated that inhibition of 
PI3K/Akt/FoxO ameliorates apoptotic cell death induced by BITC.  These results 
suggest that the PI3K/Akt/FoxO pathway negatively regulates the BITC-induced 
antiproliferation in human colorectal cancer cells.  The present results provide 
evidence that the combination of BITC with inhibitors of the survival pathway is a 
promising therapeutic strategy to overcome resistance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
14 
2. 2Materials and methods  
2.2.1 Cell culture   
HCT-116 cells and HT-29were obtained from the American Type Culture Collection 
(Manassas, VA, USA). DLD-1 cells were obtained from Tohoku University Cell 
Resource Center for Biomedical Research (Miyagi, Japan). HCT-116, HT-29 and DLD-
1 cells were maintained in DMEM (Dulbecco's modified Eagle's medium, high glucose).  
All medium were supplemented with 10% heat-inactivated FBS and 1% 
penicillin/streptomycin.  Cells were grown at 37oC in an atmosphere of 95 % O2 and 
5 % CO2.   
2.2.2 Chemicals and antibodies   
BITC were purchased from LKT Laboratories, Inc. (St. Paul, MN, USA).  
Antibodies against phosphorylated-insulin receptor β (IRβ) (Y1150/Y1151), 
phosphorylated-PI3K (Y458), phosphorylated-Akt (S473), phosphorylated-Akt (T308) 
and Akt were purchased from Cell Signaling Technology, Inc. (Beverly, MA, USA).  
Antibodies against IRβ, PI3K, phosphorylated-Foxo (S256), Foxo, actin and horseradish 
peroxidase-linked anti-rabbit and anti-mouse IgGs were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA).  LY294002 and a protein-tyrosine phosphatase 
1B (PTP1B) inhibitor (CAS 765317-72-4, PTP1B inhibitor XXII) were purchased from 
Calbiochem (Darmstadt, Germany).  NVP-BEZ235 was purchased from Selleckchem 
(Houston, Texas, USA).  Annexin-V-FLUOS stain kit was purchased from Roche. 
(Mannheim, Germany).  Propidium iodide (PI) and protease inhibitor cocktail was 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  Trypan blue stain was purchased 
from Life technologies (Carlsbad, CA, USA).  Fatal bovine serum (FBS) was purchased 
from Nichirei Corporation (Tokyo, Japan).  Bio-Rad Protein Assay was purchased from 
Bio-Rad Laboratories (Hercules, CA, USA).  Chemi-Lumi One Super was purchased 
from Nakalai Tesque Inc. (Kyoto, Japan).  All other chemicals were purchased from 
Wako Pure Chemical Industries (Osaka, Japan). 
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2.2.3 Trypan blue dye exclusion assay   
Trypan blue dye exclusion assay was carried out for quantitative analysis of cell 
viability.  Cell suspensions were mixed with 0.4% Trypan blue stain.  The total cells 
and viable cells (cells that excluded blue dye) were counted using a hemocytometer 
(Bürker-Türk, Hirschmann Laborgeräte GmbH & Co. KG, Eberstadt, Germany) under a 
light microscope. 
2.2.4 Western blot analysis   
Cells were washed with ice-cold phosphate-buffered saline without calcium and 
magnesium (PBS (-)).  Whole-cell lysates were prepared in lysis buffer (20 mM Tris-
HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM NaH2PO4, 10 mM NaF, 
2 mM Na3VO4, 1 mM PMSF, 1% SDS, 1% Sodiumdeoxycholate and 1% Triton-X-100) 
containing protease inhibitor cocktail and left on ice for 20 min.  After sonication, 
lysates were centrifuged and the supernatant was used as whole-cell lysates.  Protein 
concentration in the supernatant was determined by the Bio-Rad protein assay.  Equal 
quantities of protein were subjected to SDS-PAGE and transferred to Immobilon-P 
membrane.  The membranes were blocked and then incubated with the primary antibody 
overnight at 4oC followed by an appropriate secondary antibody.  Secondary antibody 
binding was visualized using a Chemi-Lumi One Super.  Densitometric analysis of the 
bands was carried out using the Image J Software Program (National Institutes of Health, 
Bethesda, MD, USA). 
2.2.5 Cell apoptosis analysis   
Cells were washed with ice-cold phosphate-buffered saline without calcium and 
magnesium (PBS (-)) as describe above.  After centrifuge, cells were well suspended in 
Annexin-V-FLUOS stain kit solution and incubated in the dark at room temperature for 
15 min as described in the kit manufacture.  The stained HCT-116 cells were analyzed 
by a Tali™ image-based cytometer (Life Technologies).  
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2.2.6 Cell cycle analysis   
Cells were washed with ice-cold phosphate-buffered saline without calcium and 
magnesium (PBS (-)) as describe above.  After centrifuge, cells were suspended in PI 
solution (0.1% Triton X-100, 0.2 mg/ml RNase A, 20 μg/ml PI in Dulbecco's PBS). 
2.2.7 In vitro enzymatic activity assay 
Human recombinant PTP1B was incubated with the increasing concentrations of 
BITC and glutathione (1 mM) in the dark at 37oC for 30 min.  Reaction solution (37.5 
mM HEPES (pH 7.5), 150 mM NaCl, 2,5 mM EDTA, 0.5 mM DTT, 0.1 % BSA, 50mM 
p-Nitrophenyl Phosphate) was added and then incubated for 30 min at 37oC in the dark.  
After adding NaOH (1 N) to stop the reaction, absorbance was determined by a microplate 
spectrophotometer (Bio-Rad). 
2.2.8 Statistical analysis   
The data are expressed as the means ± standard deviation (S.D.) of at least three 
independent experiments and were analyzed using Student’s t-test or Tukey test for 
comparison between groups.  P values of < 0.05 were considered to be statistically 
significant.   
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2.3 Results 
2.3.1 BITC as an activator of the PI3K/Akt/FoxO survival pathway in human colon 
cancer cells   
The HCT-116 cell line is commonly used as a colorectal cancer model because it has 
loss-of-function mutations in PI3KCA (Mueller et al., 2012).  As previously reported 
(Sakai et al., 2012), BITC dose-dependently suppressed the viability of HCT-116 cells 
(Fig. 2.1A).  Western blot analysis unexpectedly showed that the treatment of 10 μM 
BITC for 1 h increased the Akt phosphorylation at Ser473, whereas its 24-h incubation did 
not affect it (Fig. 2.1A).  To confirm this phenomenon, the phosphorylated protein levels 
of dominant molecules in the PI3K/Akt/FoxO pathway, including IRβ, PI3K, Akt and 
FoxO1, was examined.  The 1-h incubation of BITC significantly and dose-dependently 
enhanced the levels of each phosphorylated protein (Fig. 2.1B&C&D).  The treatment 
with BITC potentiated the Akt phosphorylation not only at Thr308, but also at Ser473 as 
well as its downstream target, p-FoxO1, (Fig. 2.1B&C&D), suggesting that, even though 
BITC inhibits the proliferation in human colorectal cancer cells, it actually activates the 
PI3K/Akt/FoxO pathway.  
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Fig. 2.1 BITC activated the PI3K/Akt/FoxO survival pathway  
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Fig. 2.1 BITC activated the PI3K/Akt/FoxO survival pathway. (A) Antiproliferative 
effect of BITC in HCT-116 human colorectal cancer cells.  HCT-116 cells were 
treated with the indicated concentrations of BITC for 48 h and cell viability was 
determined by trypan blue dye exclusion assay.  Effects of BITC on the expressions 
of the PI3K/Akt/FoxO signaling proteins in HCT-116 (B), HT-29 (C) and DLD-1 (D) 
cells.  HCT-116, HT-29 and DLD-1 cells were treated with the indicated concentration 
of BITC for 1 h.  Western blot analysis was performed for phosphorylated and total 
proteins of IR, PI3K, Akt and FoxO1 as well as actin. The values represent means ± 
S.D. of three separate experiments (*P < 0.05 compared with control; Student’s t-test). 
2.3.2 Enhancement of antiproliferative effect of BITC by the PI3K inhibitors   
We examined whether the antiproliferative effect of BITC is enhanced by the 
inhibition of PI3K.  A PI3K inhibitor, LY294002, and a dual PI3K/mTOR inhibitor, 
NVP-BEZ235, were utilized in combination with the BITC treatment.  As shown in Fig. 
2.2A, LY294002 and NVP-BEZ235 significantly enhanced the BITC-induced 
antiproliferation with the increasing concentration of BITC, as well as in HT-29 (D) and 
DLD-1 (F) by LY294002 only.  We next clarified the mechanism underlying the 
enhancement of the BITC-induced antiproliferation by the PI3K inhibitors, LY294002 
and NVP-BEZ235.  As shown in Figs. 2.2B and 2.2C, both LY294002 and NVP-
BEZ235 significantly enhanced the apoptosis induction by BITC, whereas they alone had 
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no effects, suggesting that the effect of these inhibitors is synergistic. LY294002 only 
showed the similar effects on BITC-induced apoptosis in HT-29 (E) and DLD-1 (G) cells.   
Consistently, as shown in Fig. 2.2C, 10 μM LY294002 and 200 nM NVP-BEZ235 
significantly potentiated the increased ratio of the Sub-G1 cell population by BITC, 
whereas they had no effects on the ratio of other cell cycle populations, such as G1, S and 
G2/M.  
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Fig. 2.2 PI3K inhibitors enhanced the antiproliferative effect of BITC 
Fig. 2.2 PI3K inhibitors enhanced the antiproliferative effect of BITC. (A, D and F) PI3K 
inhibitors further decreased the cell viability. Cells were pre-treated with LY294002 (10 
μM, A, D and F) and NVP-BEZ235 (200 nM, A) for 1 h and incubated with the indicated 
concentrations of BITC for 48 h.  Cell viability was determined by trypan blue dye 
exclusion assay.  The values represent means ± S.D. of three separate experiments.  
Different letters above the bars indicate significant differences among treatments for 
each compound (P > 0.05).  (B, C, E and G) PI3K inhibitors enhanced the BITC-
induced apoptotic cell death.  Cells were pre-treated with LY294002 (10 μM, B, E and 
G) or NVP-BEZ235 (200 nM, B) for 1 h and incubated with or without BITC (10 μM) 
for 48 h.  Apoptosis was detected by an Annexin-V-FLUOS stain kit and analyzed by 
a Tali™ image-based cytometer.  (D) PI3K inhibitors enhanced the BITC-induced 
appearance of the sub-G1 population.  HCT-116 cells were pre-treated with LY294002 
(10 μM) or NVP-BEZ235 (200 nM) for 1 h and incubated with or without BITC (10 μM) 
for 48h.  Cell cycle analysis was done by PI staining and Tali™ image-based cytometer.  
The values represent means ± S.D. of three separate experiments.  Data were analyzed 
by a one-way ANOVA followed by Tukey’s HSD using XLSTAT software.  Different 
letters above the bars indicate significant differences among treatments for each 
compound (P > 0.05). 
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2.3.3. Attenuation of the BITC-induced PI3K/Akt/FoxO pathway by the PI3K inhibitors  
Since the PI3K inhibitors, LY294002 and NVP-BEZ235, significantly enhanced the 
apoptosis induction by BITC, we next confirmed that these two inhibitors actually 
attenuate the PI3K/Akt/FoxO survival pathway.  As shown in Fig. 2.3A&C&D, 
LY294002 significantly inhibited the BITC-induced phosphorylation of Akt at both 
Thr308 and Ser473 and its downstream target FoxO.  Similarly, but more potently, the dual 
PI3K/mTORC2 inhibitor, NVP-BEZ235, attenuated the BITC-induced phosphorylation 
of Akt and FoxO (Fig. 2.3B).  Compared to the effect of LY294002, NVP-BEZ235 
completely diminished the phosphorylation of Akt at Ser473 and FoxO, which might be 
due to the dual inhibitory function against PI3K and mTORC2.  
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Fig. 2.3.  PI3K inhibitors suppressed the BITC-induced phosphorylation of Akt and 
FoxO 
Fig. 2.3.  PI3K inhibitors suppressed the BITC-induced phosphorylation of Akt and 
FoxO.  Cells were pre-treated with LY294002 (10 μM, A, C and D) or NVP-BEZ235 
(200 nM, B) for 1 h and incubated with the indicated concentrations of BITC for 1 h.  
Western blot analysis was performed for the phosphorylated and total proteins of Akt 
and FoxO1 as well as actin.  The values represent means ± S.D. of three separate 
D 
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experiments.  Different letters above the bars indicate significant differences among 
treatments for each compound (P > 0.05, Tukey’s HSD). 
2.3.4. Inhibition of MEK/ERK pathway failed to enhance antiproliferation by BITC 
Mitogen-activated protein kinases (MAPKs) are serine-threonine kinases that 
mediate intracellular signaling associated with a variety of cellular activities (Saltiel and 
Kahn, 2001).  Contrast to other MAPKs but similar to the PI3K/Akt pathway, the 
MEK/ERK signaling cascade plays a significant role cell growth and differentiation (Kim 
and Choi, 2010; Zhang and Liu, 2002), which is activated by receptor tyrosine kinases 
(RTK), including insulin receptor (Boucher et al., 2014; Saltiel and Kahn, 2001; Zhang 
et al., 2011).  Since BITC significantly enhanced the phosphorylation of IRβ, we 
examined whether the ERK pathway is activated by BITC and modulate the BITC-
induced antiproliferation.  As shown in Figs. 2.4A, BITC significantly enhanced the 
phosphorylation of ERK and PD98059, a MEK inhibitor, significantly inhibited the 
enhanced p-ERK level.  However, co-treatment of BITC with PD98059 failed to affect 
the BITC-induced antiproliferation (Fig. 2.4B and 2.4C).  Consistently, the treatment of 
PD98059 had no effect on the ratio of the apoptosis population as well as normal cell 
population.  
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Collectively, the BITC-enhanced ERK signaling pathway could be ruled out in 
the negative regulation of the BITC-induced antiproliferation. 
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Fig. 2.4 Inhibition of MEK/ERK pathway failed to enhance antiproliferation by BITC 
Fig 2.4 Inhibition of MEK/ERK pathway failed to enhance antiproliferation by BITC. 
(A) PD98059 attenuated the BITC-induced phosphorylation of ERK.  HCT-116 cells 
were pre-treated with PD98059 (10 μM) for 1 h and incubated with the indicated 
concentrations of BITC for 1 h.  Western blot analysis was performed for the 
phosphorylated and total proteins of ERK as well as actin.  The values represent means 
± S.D. of three separate experiments.  Different letters above the bars indicate 
significant differences among treatments for each compound (P > 0.05, Tukey’s HSD).   
(B) A MEK inhibitor failed to enhance BITC-induced antiproliferation. HCT-116 cells 
were pre-treated with or without PD98059 (10 μM) for 1 h and incubated with the 
indicated concentrations of BITC for 48 h.  Cell viability was determined by trypan 
blue dye exclusion assay.  The values represent means ± S.D. of three separate 
experiments (*P < 0.05 compared with control; Student’s t-test).  (C) PD98059 failed 
to enhance the BITC-induced apoptosis.  HCT-116 cells were treated with PD98059 
(10 μM) for 1 h and incubated with or without BITC (10 μM) for 48 h.  Apoptosis was 
detected by an Annexin-V-FLUOS stain kit and analyzed by a Tali™ image-based 
cytometer.  The values represent means ± S.D. of three separate experiments.  
Different letters above the bars indicate significant differences among treatments for 
each compound (P > 0.05, Tukey’s HSD). 
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2.3.5. Potentiation of the PI3K/Akt/FoxO pathway by BITC through PTP1B inhibition   
PTP1B has been suggested as an attractive target to improve insulin sensitivity by 
modulation of the downstream kinase cascade in different cell types (Través et al., 2014).  
As shown in Fig. 2.4A, BITC inhibited the human recombinant PTP1B enzyme activity 
in a dose-dependent manner.  Consistently, BITC potentiated the phosphorylation levels 
of IRβ, PI3K and Akt at Ser473 not only at the basal level, but also at the insulin-enhanced 
level (Figs. 2.4B).  This tendency is quite similar to that of PTP1B inhibitor XXII, 
suggesting that BITC enhanced the PI3K/Akt/FoxO pathway by a mechanism similar to 
that of the PTP1B inhibitor.  
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Fig. 2.5. BITC potentiated the activation of the PI3K/Akt/FoxO pathway by PTP1B 
inhibition 
Fig. 2.5. BITC potentiated the activation of the PI3K/Akt/FoxO pathway by PTP1B 
inhibition. (A) BITC inhibited PTP1B enzymatic activity in vitro.  Human recombinant 
PTP1B was incubated with the indicated concentrations of BITC and glutathione (1 mM) 
for 30 min at 37oC in the dark, then incubated with reaction solution in the dark at 37oC 
for 10 mins.  After adding NaOH (1 N) to stop the reaction, absorbance was measured 
by a microplate spectrophotometer.  The values represent means ± S.D. of three 
separate experiments (*P < 0.05 compared with control; Student’s t-test).  (B) BITC 
enhanced the insulin-induced phosphorylation of PI3K/Akt/FoxO signaling proteins.  
HCT-116 cells were pre-treated with PTP1B inhibitor (20 μM) or BITC (10 μM) for 1 h 
and incubated with or without insulin (200 nM) for 10 min.  Western blot analysis was 
performed for the phosphorylated and total proteins of IR, PI3K, Akt and FoxO1 as well 
as actin. The values represent means ± S.D. of three separate experiments.  Different 
letters above the bars indicate significant differences among treatments for each 
compound (P > 0.05, Tukey’s HSD) 
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2.4. Discussion  
As already mentioned, BITC has been shown to have antiproliferative properties 
against various cell lines including colorectal cancer cells (Abe et al., 2014; Sakai et al., 
2012).  Consistent with these reports, we also observed that BITC significantly inhibited 
the viability of human colorectal cancer HCT-116 cells (Fig. 2.1A).  At the same time, 
BITC significantly potentiated the phosphorylation of the member proteins in the 
PI3K/Akt/FoxO pathway.  BITC not only enhanced the phosphorylation of IRβ, but also 
initiated a cascade of phosphorylation events, resulting in the phosphorylation of PI3K 
and Akt at Thr308 (Fig. 2.1B).  BITC also enhanced the level of p-AktS473, suggesting 
that Akt is fully activated and led to the phosphorylation of its downstream target, FoxO1.  
BITC enhanced PI3K/Akt/FoxO not only in HCT-116 cells, but also in another two 
human colorectal cancer cell line, HT-29 and DLD-1 (Fig. 2.2C and 2.2D).  Previous 
studies showed that the treatment of BITC for 24 h or the longer period could decrease 
the phosphorylation levels of PI3K and Akt in HT29 cells (Lai et al., 2010) as well as in 
human pancreatic cancer cell lines (Boreddy et al., 2011), whereas the effect of its 
incubation for less than a few hours remained to be determined.  To the best of our 
knowledge, this is the first report showing the activation of the IRβ/PI3K/Akt/FoxO axis 
by BITC in human colorectal cancer cells. 
The PI3K/Akt/FoxO pathway is one of the most famous cell survival pathways that 
negatively regulate the anti-proliferation and apoptosis induction by anti-tumor agents 
(Jian et al., 2015).  It has been reported that anti-tumor agents inhibit cell proliferation 
by induction of apoptosis through inhibition of the PI3K/Akt/FoxO pathway in human 
pancreatic (Boreddy et al., 2011) and colorectal cancer cells (Luo et al., 2013), in which 
the phosphorylated proteins of PI3K, Akt and FoxO are highly expressed.  The fact that 
BITC enhanced the PI3K/Akt/FoxO pathway (Fig. 2.1B, 2.1C and 2.2D) led to the 
hypothesis that the PI3K/Akt/FoxO survival pathway is not involved in the 
antiproliferation mechanism, but rather contributes to the resistance against BITC.  
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This idea was supported by the observation that the antiproliferation by BITC was 
significantly enhanced by the PI3K inhibitors at a non-cytotoxic concentration (Fig. 
2.2A, 2.2D and 2.2F), but sufficient for attenuation of the Akt phosphorylation (Figs. 
2.3A, 2.3B, 2.3C and 2.3D).  Furthermore, the combination with the PI3K inhibitors 
synergistically enhanced the BITC-induced apoptosis in HCT-116, HT-29 and DLD-1 
cells (Figs. 2.2B, 2.2E and 2.2G).  A similar result was also obtained by a cell cycle 
analysis (Fig. 2.2C). These results suggested that the inhibition of the PI3K/Akt/FoxO 
pathway might contribute to enhancement of the apoptosis-inducing signaling in human 
colorectal cancer cells.  Another essential signaling pathway branched from IR is the 
MAPK/ extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling 
cascade, which also plays a significant role in cell growth and differentiation (Kim and 
Choi, 2010; Zhang and Liu, 2002).  Although BITC enhanced the phosphorylation of 
ERK in HCT-116 cell lines, the MEK inhibitor, PD98059, had no effect on the 
antiproliferation and apoptosis induction by BITC (Fig. 2.4B and 2.4C), suggesting that 
the ERK signaling cascade could be ruled out in the mechanism of the BITC resistance. 
The endoplasmic reticulum-targeted protein tyrosine phosphatase PTP1B is 
particularly essential in the IR regulation due to its ability to dephosphorylate the 
phosphorylated IR, thereby switching off insulin signaling.  PTP1B regulates a wide 
variety of cellular processes including cell growth, cell proliferation and 
apoptosis/survival decisions (Koren and Fantus, 2007).  Mice lacking the PTP1B 
enzyme activity exhibit an enhanced insulin sensitivity, attributable to an increased IR 
phosphorylation in the liver and muscle (Elchebly et al., 1999).  We demonstrated that 
BITC dose-dependently inhibited the human recombinant PTP1B activity in vitro (Fig. 
2.5A).  Consistently, BITC as well as the PTP1B inhibitor enhanced the 
phosphorylation of the downstream targets (Fig. 2.5B).  These results strongly 
suggested that BITC might sensitize not only the basal activation, but also the insulin-
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induced activation of the PI3K/Akt/FoxO pathway, possibly through the PTP1B 
inhibition.   
In conclusion, we demonstrated the negative regulating role of the PI3K/Akt/FoxO 
pathway in antiproliferation induced by BITC in human colorectal cancer cells.  
Inhibitory experiments using the PI3K inhibitors at a non-toxic concentration indicated 
that inhibition of the PI3K/Akt/FoxO pathway synergistically ameliorates the apoptotic 
cell death induced by BITC.  The present results provide evidence that the 
combination with inhibitors of the PI3K/Akt/FoxO survival pathway is a promising 
therapeutic strategy to overcome resistance against food-derived anticancer compounds.  
Future efforts will be concerned with further understanding the signaling pathway of 
the apoptosis induction as well as the in vivo significance of the ameliorating effect of 
the PI3K inhibitors on several rodent models. 
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CHAPTER 3 
A link between benzyl isothiocyanate-induced autophagy and Nrf2/Keap1 
regulation in human colon cancer cells 
3.1 Introduction 
Nuclear factor-erythroid 2 (NF-E2)-related factor 2 (Nrf2)-kelch-like ECH-
associated protein 1 (Keap1)-antioxidant response element (ARE) pathway plays a 
pivotal role in the inducible expression of cytoprotective genes in response to oxidative 
stress, environmental xenobiotics, and toxic chemicals.(Nakamura and Miyoshi, 2010)  
Keap1-Cul3 E3 ubiquitin ligase complex mediates the proteasomal degradation of Nrf2 
under basal conditions, whereas, under stress conditions, Nrf2 is translocated into 
nucleus in a Keap1-dependent or -independent manner, followed by transcriptional 
activation of ARE genes.  Oxidative stress and electrophilic chemicals specifically 
target reactive cysteine residues of Keap1 and lead to release of Nrf2 from the Nrf2-
Keap1-Cul3 complex through its conformational change and thus enhanced Nrf2 
nuclear translocation (Keap1-dependent canonical pathway).(Qin and Hou, 2016)   
Autophagy is a physiological pathway for lysosomal degradation and recirculation 
in which cellular components, misfolded proteins, and damaged organelles are delivered 
to double-membrane vesicles called autophagosomes.(Sui et al., 2011)  Autophagy is 
also induced by a variety of stresses, including oxidative stress, ER stress, pathogens, or 
nutrient deprivation to defend against them and thus preserves cellular homeostasis.  
Selective substrate adaptor proteins, such as p62/sequestosome 1(SQSTM1), have been 
shown to facilitate degradation of specific proteins through autophagy,(Ichimura et al., 
2008) in addition to its non-selective degradation role.  p62 binds directly to 
microtubule-associated protein 1 light chain 3 (LC3), a representative marker of the 
autophagosome, that is cleaved (LC3-I) and conjugated to phosphatidylethanolamine 
(LC3-II).(Pankiv et al., 2007)  p62 interacts with ubiquitylated protein aggregates and 
delivers them to the autophagosomes,(Jiang et al., 2015) indicating an important role for 
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p62 in autophagic protein degradation.  Although the Keap1-dependent canonical Nrf2 
regulation is regarded as the primary mode of action for cytoprotection, p62 also 
regulates the activation of Nrf2 signaling pathway by Keap1 binding and transferring into 
the autophagosomes for degradation in an autophagy-dependent manner (noncanonical 
pathway).(Ma, 2013; Wasik et al., 2017)   
Isothiocyanates (ITCs), derived from various cruciferous vegetables, are regarded 
as potential preventive agents against carcinogenesis, because they are capable of up-
regulating the xenotiotic-detoxifying enzymes, inducing apoptosis, and inhibiting cell 
cycle progression.(Nakamura and Miyoshi, 2010)  Benzyl isothiocyanate (BITC), an 
ITC compound from papaya seeds,(Nakamura et al., 2007a) has been shown not only 
to inhibit cell proliferation in T lymphocytes,(Miyoshi et al., 2004b) renal proximal 
tubular cells,(Abe et al., 2012) and colorectal cancer cells,(Abe et al., 2014; Sakai et al., 
2012) but also to induce the phase 2 drug-metabolizing enzyme.(Nakamura et al., 2000)  
BITC has recently been reported to induce autophagy in human lung cancer cells(Zhang 
et al., 2017) and human breast cancer cells.(Xiao et al., 2012)  Although Keap1 is 
thought to be the major target for Nrf2 activation by ITCs such as sulforaphane, the 
regulating role of autophagy in BITC-induced Nrf2 activation remains unclear.  
In this study, we demonstrated that BITC dose-dependently induced autophagy 
and p62 expression, concomitantly with Keap1/Nrf2 modulation in human colorectal 
cancer HCT-116 cells.  We also clarified the mediating role of phosphatidylinositide 
3-kinase (PI3K) between autophagy induction and Nrf2 activation by BITC.   
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3.2 Materials and Methods  
3.2.1Cell Culture.  
HCT-116 cells were obtained from the American Type Culture Collection (Manassas, 
VA, USA).  HCT-116 cells were maintained in DMEM (Dulbecco's modified Eagle's 
medium, high glucose).  All medium were supplemented with 10% heat-inactivated 
FBS and 1% penicillin/streptomycin.  Cells were grown at 37oC in an atmosphere of 
95 % O2 and 5 % CO2.   
3.2.2 Chemicals and Antibodies.  
BITC were purchased from LKT Laboratories, Inc. (St. Paul, MN, USA).  Antibodies 
against LC3B, LAMP1 and Nrf2 were purchased from Cell Signaling Technology, Inc. 
(Beverly, MA, USA). Antibodies against Keap1, P62, actin and horseradish peroxidase-
linked anti-rabbit, anti-mouse and anti-goat IgGs were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA).  Wortmannin and protease inhibitor cocktail 
was purchased from Sigma-Aldrich (St. Louis, MO, USA).  Fatal bovine serum (FBS) 
was purchased from Nichirei Corporation (Tokyo, Japan).  Bio-Rad Protein Assay was 
purchased from Bio-Rad Laboratories (Hercules, CA, USA).  Chemi-Lumi One Super 
was purchased from Nakalai Tesque Inc. (Kyoto, Japan).  All other chemicals were 
purchased from Wako Pure Chemical Industries (Osaka, Japan). 
3.2.3 Western Blot Analysis.  
   See chapter 2. 
3.2.4Immunofluorescence.  
Cells were incubated in 4% Paraformaldehyde (PFA)/PBS for 30 min. After fixation, cells 
were incubated in 0.05% TritonX-100/PBS for 10 min and then incubated in 3% 
BSA/PBS for 1h. Cells were incubated with the primary antibody overnight at 4oC 
followed by an appropriate secondary antibody conjugated with FITC. After wash by 
distilled water, cells were mounted by Fluoroshield Mounting Medium with DAPI and 
visualized under fluorescence microscope (Keyence).  
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3.2.5MDC staining.  
Cells were washed with ice-cold phosphate-buffered saline without calcium and 
magnesium (PBS (-)). Autophagic vacuoles were then labeled with dansylcadaverine 
(MDC) by incubating cells with 0.05 mM MDC at 37oC for 10 min. After incubation, 
cells were visualized under fluorescence microscope (Keyence). 
3.2.6 RNA extraction and RT-PCR.  
Total RNA was extracted using Trizol reagent according to the manufacturer’s manual 
and reverse transcribed to cDNA using ReverTra Ace.  PCR amplification was then 
performed with Taq polymerase.  Primers used in PCR ampliﬁcation are as follows: 
human hemeoxygenase 1 (hHO-1), (F) 5’-AAGATTGCCCAGAAAGCCCTGGAC-3’ 
and (R) 5’-AACTGTCGCCACCAGAAAGCTGAG-3’; human β-actin, (F) 5’-
GTCACCCACACTGTGCCCATCTA-3’ and (R) 5’-
GCAATGCCAGGGTACATGGTGGT -3’.  The PCR product were separated on an 
agarose gel (3%), stained with ethidium bromide, and visualized under UV light.  The 
relative densities of bands were measured using Image J Software Program. 
3.2.7 Statistical Analysis.  
The data are expressed as the means ± standard deviation (S.D.) of at least three 
independent experiments and were analyzed using Student`s t-test or Tukey test for 
comparison between groups. P values of < 0.05 were considered to be statistically 
significant.   
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3.3 Results 
3.3.1 BITC induced the accumulation of autophagic molecules in HCT-116 cells 
Initial experiments using human colorectal cancer cells showed that BITC enhanced 
the protein levels of representative molecules of autophagy, including p62, LAMP1 as 
well as the conversion of LC3BI into LC3BII in a time-dependent manner up to 12 h (Fig. 
3.1A).  As shown in Figs. 3.1B, BITC dose-dependently enhanced protein levels of 
LC3BII and LAMP1, which suggested that BITC might induced the formation of 
autophagosome and lysosome. In addition, due to recent studies that the crosslink 
between Nrf2-Keap1-ARE axis with autophagy, I also found that BITC concomitantly 
induced p62 and Nrf2 up-regulation and Keap1 down-regulation.  These results 
suggested that BITC induced not only autophagy, but also Nrf2 pathway activation in 
HCT-116 cells.   
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Fig.3.1 BITC enhanced protein levels of representative molecules of autophagy and 
activated p62-related Nrf2/Keap1 pathway 
Fig.3.1 BITC enhanced protein levels of representative molecules of autophagy and 
activated p62-related Nrf2/Keap1 pathway. (A). Time-dependent induction of auphagic 
molecules by BITC. HCT-116 cells were treated with the indicated period of 20 μM 
BITC. Western blot analysis was performed for proteins of p62, LC3B and LAMP1 as 
well as actin. (B). Induction of autophagic molecules by BITC in HCT-116 cancer cells. 
HCT-116 cells were treated with the indicated concentrations of BITC for 12 h. Western 
blot analysis was performed for proteins of LC3B and LAMP1 as well as actin. (C) 
Activation of p62-Nrf2-Keap1 axis by BITC. HCT-116 cells were treated with the 
indicated concentrations of BITC for 12 h. Western blot analysis was performed for 
proteins of p62, Nrf2 and Keap1 as well as actin. The values represent means ± S.D. of 
three separate experiments (*P < 0.05 compared with control; Student’s t-test). 
3.3.2 BITC induced the accumulation of autophagic compartments in HCT-116 cells 
To further examine BITC-induced autophagy, we performed immunostaining with 
anti-LC3B and anti-LAMP1 antibodies. HCT-116 cells were treated with BITC for 12 h. 
Immunocytochemistry experiments showed that the incubation of BITC for 12 h resulted 
in the increment in puncta of LC3B and LAMP1 (Fig. 3.2A) , further supporting the idea 
that BITC induces the formation of autophagosome and lysosome. The cytosolic MDC 
staining observed under fluorescence microscope were determined that revealed BITC 
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induced accumulation of autophagic vacuoles in a dose-dependent manner (Fig. 3.2B).  
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Fig. 3.2 BITC induced formation and accumulation of autophagic compartments in 
HCT-116 cancer cells 
Fig. 3.2 BITC induced formation and accumulation of autophagic compartments in 
HCT-116 cancer cells. (A). BITC induced formation of autophagome and lysosome. 
HCT-116 cells were treated with the indicated concentrations of BITC for 12 h. cells 
were immuno-fluorescently labeled and imaged using a fluorescence microscope. LC3B 
and LAMP1 represents formation of autophagosome and lysosome, respectively. (B) 
Induction of autophagic vacuoles by BITC. HCT-116 cells were treated with the 
indicated concentrations of BITC for 12 h before MDC staining. Cells were visualized 
under fluorescence microscope. The number of cells with a granular positive MDC 
staining was counted (a minimum of 100 cells/sample). The values represent means ± 
S.D. of three separate experiments (*P < 0.05 compared with control; Student’s t-test). 
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3.3.3 PI3K inhibitor wortmannin attenuated BITC-enhanced conversion of LC3B and 
autophagic vacuoles in HCT-116 cells. 
Class III PI3K (PIK3C3/Vps34) has been strongly implicated in autophagic 
processes in mammals.(Itakura et al., 2008)  Both LC3B and p62 are prerequisite for the 
biosynthesis of autophagosome, which is also regulated by PI3K.(Kim and Choi, 2010)  
Wortmannin, a selective PI3K inhibitor, has been reported to possess effects on the 
inhibition of autophagy in diverse cancer cell lines.(Huang et al., 2016; Zhou et al., 2017; 
Zhu et al., 2017)  As shown in Fig. 3.2B, wortmannin significantly attenuated the BITC-
induced conversion of LC3B in a non-cytotoxic concentration (Fig. 3.2A), implying that 
PI3K is involved in the BITC-induced autophagy in HCT-116 cells. In addition, MDC 
staining results, as shown in Fig 3.3C, suggested wortmannin significantly attenuated 
the BITC-induced autophagic vacuoles in HCT-116 cells. 
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Fig. 3.3 Wortmannin attenuated BITC-induced conversion of LC3B and autophagic 
vacuoles in HCT-116 cells. 
Fig 3.3 Wortmannin attenuated BITC-induced conversion of LC3B and autophagic 
vacuoles in HCT-116 cells. (A). Wortmannin (50nm) had no effects on cell viability in 
HCT-116 cells. HCT-116 cells were pre-treated with wortmannin (50 nM) for 1 h and 
incubated with the indicated concentrations of BITC for 24 h. Cell viability was measured 
by MTT assay. (B). Wortmannin attenuated BITC-induced autophagic molecules. HCT-
116 cells were pre-treated with wortmannin (50 nM) for 1 h and incubated with the 
indicated concentrations of BITC for 12 h.  Western blot analysis was performed for 
proteins of LC3B as well as actin. (C). Wortmannin attenuated BITC-induced 
autophagic vacuoles. HCT-116 cells were pre-treated with wortmannin (50 nM) for 1 h 
and incubated with the indicated concentrations of BITC for 12 h before MDC staining. 
Cells were visualized under fluorescence microscope. The number of cells with a 
granular positive MDC staining was counted (a minimum of 100 cells/sample). The 
values represent means ± S.D. of three separate experiments.  Different letters above 
the bars indicate significant differences among treatments for each compound (P > 0.05, 
Tukey’s HSD). 
3.3.4 PI3K inhibitor wortmannin attenuated BITC-induced p62-Nrf2-Keap1 pathway in 
HCT-116 cells. 
We next examined whether the PI3K inhibitor could affect the Keap1/Nrf2 
pathway.  As shown in Fig. 2, wortmannin completely impaired the BITC-induced 
accumulation of protein levels of p62 and Nrf2, coincided with the full recovery of down-
regulated Keap1 (Fig. 3.4A).  Furthermore, wortmannin significantly impaired the 
BITC-induced up-regulation of the gene expression of HO-1, one of the representative 
Nrf2-regulated genes (Fig. 3.4B).  These results suggested that PI3K plays the key role 
in the autophagy-dependent Nrf2 activation by BITC. 
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Fig. 3.4 PI3K inhibitor wortmannin attenuated BITC-induced p62-Nrf2-Keap1 pathway 
in HCT-116 cells 
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Fig. 3.4 PI3K inhibitor wortmannin attenuated BITC-induced p62-Nrf2-Keap1 
pathway in HCT-116 cells. (A). Wortmannin attenuated BITC-induced actication of 
p62-Nrf2-Keap1 pathway. HCT-116 cells were pre-treated with wortmannin (50 nM) for 
1 h and incubated with the indicated concentrations of BITC for 12 h.  Western blot 
analysis was performed for proteins of p62, Nrf2 and Keap1 as well as actin. (B). 
Wortmannin attenuated BITC-induced HO-1 gene expression. HCT-116 cells were pre-
treated with wortmannin (50 nM) for 1 h and incubated with the indicated concentrations 
of BITC for 12 h.  RT-PCR was performed for HO-1 as well as actin.   The values 
represent means ± S.D. of three separate experiments.  Different letters above the bars 
indicate significant differences among treatments for each compound (P > 0.05, 
Tukey’s HSD). 
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Discussion  
   Autophagy is responsible for scavenging and degrading of damaged organelles, long-
lived proteins, for misfolded proteins, which also plays an essential role in eliminating 
intracellular pathogens to maintain the cellular longevity (Mizushima et al., 2008). Given 
its critical roles, it is extremely important to investigate its underlying mechanism in 
cancer cells. In the present study, we found BITC dose-dependently induced 
accumulation of autophagic molecules (Fig.3.1 B), which reached the maximum level at 
12 h. (Fig. 3.1A). Moreover, we morphologically confirmed that BITC induced not only 
the formation of autophagosome and lysosome (Fig. 3.2A) but also the formation of 
autophagic vacuoles (Fig. 3.2B). On the other hand, induction of p62 by BITC (Fig. 3.1A) 
suggested that p62/Nrf2 pathway might be involved in BITC-induced autophagy in HCT-
116 cells. Surprisingly, our results indicated that p62-Nrf2-Keap1 axis was activated by 
a noncanonical pathway (Fig.3.1C). 
     In general, both LC3B and p62 are necessarily required for the biosynthesis of 
autophagosome which is regulated by PI3-kinase (Funderburk et al., 2010). Once we 
found that BITC induced autophagy in HCT-116 cells, we hypothesized that PI3K might 
be involved in BITC-induced autophagy. The idea was supported by the investigation that 
PI3K inhibitor wortmannin inhibited the accumulation of LC3B (Fig. 3.3A), autophagic 
vacuoles (Fig. 3.3B) and p62 (Fig. 3.4A) in a non-toxic concentration (Fig. 3.3A), 
indicating that PI3K was involved in the mechanism in BITC-induced autophagy. On the 
other hand, the inhibition of BITC-induced accumulation of p62 by wortmannin also 
attenuated BITC-induced noncanonical p62-Nrf2-Keap1 pathway (Fig. 3.4 A). The 
noncanonical Nrf2/Keap1 pathway contributes to the activation of Nrf2, which was also 
confirmed by the found that inhibition of Nrf2 by equivalent amount of wortmannin 
resulted in attenuation of BITC-induced HO-1 gene expression (Fig. 3.4 B). These results 
suggested that BITC triggered autophagic effect in PI3K-associated mechanism through 
a p62-dependent Nrf2/Keap1 pathway in HCT-116 cells.   
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In conclusion, we demonstrated that BITC activated the Nrf2 pathway in an 
autophagy-dependent manner (noncanonical pathway) in human colorectal cancer HCT-
116 cancer cells.  The present data suggested that PI3K plays an essential role in 
association between Nrf2/Keap1 pathway and autophagy in HCT-116 cells.  Drug 
resistance often limits the efficacy as well as outcome of chemotherapy.  The 
increasing metabolism and efflux of the drug as well as PI3K mediates resistance to the 
chemotherapy drugs.(Gottesman et al., 2002)  The PI3K-mediated pathway is 
frequently activated(Boreddy et al., 2011; Fahy et al., 2003) and influences cell growth, 
survival and drug resistance(Jian et al., 2015) in a variety of human cancer cells 
including colorectal cancer cells.  Nrf2 activation also can enhance the resistance of 
cancer cells to chemotherapeutic drugs.(Huang et al., 2015; Nakamura and Miyoshi, 
2010)  Therefore, the present results provide evidence that the combination with the 
PI3K inhibitor is a potential strategy to overcome resistance against food-derived 
anticancer compounds activating the Nrf2 pathway.   
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CONCLUSION 
    In the present study, the role of the PI3K/Akt/FoxO pathway in antiproliferation 
induced by BITC was investigated in human colorectal cancer cells. I also investigated 
the role of PI3K in BITC-related autophagy and its association with autophagy-related 
Nrf2/Keap1 pathway in human colorectal cancer cells. 
    
 In chapter 2, the role of the PI3K/Akt/FoxO pathway in antiproliferation induced 
by BITC in human colorectal cancer cells was investigated. The results are summarized 
as followed 
(1) BITC exhibited anti-proliferative effect on human HCT-116 cells, whereas 
simultaneously activated PI3K/Akt/FoxO survival pathway in HCT-116, HT-
29 and DLD-1 human colon cancer cells. 
(2) Inhibition of PI3K/Akt pathway enhanced BITC-induced anti-proliferation in 
HCT-116, HT-29 and DLD-1 cells. 
(3) MEK/ERK pathway was ruled out in the mechanism of BITC-induced drug 
resistance in human colon cancer cells. 
(4) BITC significantly decreased PTP1B enzyme activity and enhanced sensitivity 
to insulin-induced PI3K/Akt/FoxO pathway as a PTP1B inhibitor. 
The present results provide evidence that the combination with inhibitors of the 
PI3K/Akt/FoxO survival pathway is a promising therapeutic strategy to overcome 
resistance against food-derived anticancer compounds. 
    In chapter 3, I investigated the effect of BITC on autophagy in HCT-116 colon 
cancer cells and the role of PI3K in BITC-related autophagy and its association with 
autophagy-related Nrf2/Keap1 pathway. The results are summarized as followed. 
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(1) BITC enhanced the protein levels of representative molecules of autophagy, 
including p62, LC3BII and LAMP1 in a time-dependent manner up to 12 h. 
(2) BITC activated the Nrf2 pathway in an autophagy-dependent manner 
(noncanonical pathway) in human colorectal cancer HCT-116 cancer cells. 
(3) Inhibition of PI3K attenuated BITC-induced accumulation of autophagic 
molecules, accumulation of p62 and Nrf2 and HO-1 gene expression in human 
HCT-116 colon cancer cells. 
The present results provide evidence that the combination with the PI3K inhibitor 
is a potential strategy to overcome resistance against food-derived anticancer 
compounds activating the Nrf2 pathway. 
Taken together, these series of studies suggested that PI3K exceedingly contributed 
to drug-induced resistance not only in regulation of PI3K/Akt pathway but also in 
controlling in Nrf2/Keap1-related cellular detoxifying effects in human colorectal 
cancer cells. Combinative treatments with PI3K inhibitor are a potential strategy to 
overcome resistance against food-derived anticancer compound. 
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